Back to results
US 2013/0045979 A1Published application
Method of treating major depressive disorder
AssigneeLcs Group, LLC
InventorLouis Sanfilippo
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeLcs Group, LLC
InventorLouis Sanfilippo
Estimating the term…
The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.
(canceled)
A method of treating major depressive disorder comprising (i) diagnosing a patient as having major depressive disorder and as failing to achieve remission in response to antidepressant therapy and (ii) administering to the patient an effective amount lisdexamfetamine dimesylate together with an additional active agent, wherein the additional active agent is an antidepressant, and the effective amount is an amount effective in a clinical trial of efficac of lisdexamfetamine dimes late for treating major depressive disorder, in which data is submitted to the FDA.
3-5. (canceled)
(canceled)
(canceled)
The methods of claim 52, wherein the additional active agent an antidepressant chosen from mirtazapine, escitalopram, fluoxetine, sertraline, citalopram, bupropion, venlafaxine, duloxetine, and the pharmaceutically acceptable salts and hydrates of any of the foregoing.
15-16. (canceled)
A method of using lisdexamfetamine dimesylate comprising informing a user that the lisdexamfetamine dismesylate may be used to treat major depressive disorder.
21-26. (canceled)
A method of using lisdexamfetamine dimesylate comprising (i) conducting a clinical trial of the efficacy lisdexamfetamine dimesylate for treating major depressive disorder and (ii) informing a purchaser of the lisdexamfetamine dismesylate that the lisdexamfetamine dismesylate is efficacious for treating major depressive disorder.
(canceled)
Dependencies are inferred from the claim text.